Experience with an external quality assurance scheme for antimicrobial susceptibility testing of Neisseria gonorrhoeae in India, 2001-2007

Epidemiology and Infection

Volumn 138, Issue 1, 2010, Pages 69-75

  Bala, M ^a   Tapsall, J W ^b   Limnios, A ^b   Sood, S ^c   Ray, K ^a  

^a SAFDARJUNG HOSPITAL   (India)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antibiotic resistance; Infectious disease control; Neisseria gonorrhoea; Public health microbiology; Sexually transmitted infections

Indexed keywords

CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; NALIDIXIC ACID; PENICILLIN G; SPECTINOMYCIN; TETRACYCLINE;

ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DISEASE CONTROL; INDIA; NEISSERIA GONORRHOEAE; NONHUMAN; QUALITY CONTROL; DRUG EFFECT; HEALTH CARE QUALITY; HUMAN; MICROBIOLOGICAL EXAMINATION; STANDARD; STATISTICS;

HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; QUALITY CONTROL; QUALITY INDICATORS, HEALTH CARE;

EID: 73349104637     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268809990148     Document Type: Article

References (20)

1. Tapsall J. Antimicrobial resistance in Neisseria gonorrhoeae. WHO/CDS/CSR/DRS/2001.3. Geneva: World Health Organization, 2001.
2. Tapsall J. What is the economic burden imposed by antimicrobial resistance in Neisseria gonorrhoeae? ReACT group, 2005 (http://react-group.org/ dyn//, 10,.html). Accessed 14 March 2009.
3. Bala M, Ray K, Kumari S. Alarming increase in ciprofloxacin and penicillin resistant Neisseria gonorrhoeae isolates in New Delhi, India. Sexually Transmitted Diseases 2003; 30: 523-525.
4. Tapsall JW. Surveillance of antibiotic susceptibility of Neisseria gonorrhoeae in the WHO western pacific region 1992-4. Genitourinary Medicine 1997; 73: 355-361.
5. WHO. Global Surveillance Network for Gonococcal Antimicrobial Susceptibility. WHO/VDT/90-452. Geneva: World Health Organization, 1990.
6. WHO Gonococcal Antimicrobial Surveillance Programme. Rationale and applications for the current (2008) WHO panel of Neisseria gonorrhoeae for antimicrobial resistance surveillance for public health purposes, and instructions for their use. Technical document D007-0408-1#1, 2008, World Health Organization Collaborating Centre for STD, Sydney, Australia.
7. Unemo M, et al. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance (AMR) surveillance for public health purposes. Journal of Antimicrobial Chemotherapy 2009; 63: 1142-1151.
8. Muratani T, et al. Outbreak of cefozopran (penicillin, oral cephems and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrobial Agents and Chemotherapy 2001; 45: 3603-3606.
9. Lo JYC, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrobial Agents and Chemotherapy 2008; 52: 3564-3567.
10. Workowski KA, Berman SM, Douglas Jr. JM. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Annals of Internal Medicine 2008; 148: 606-613.
11. Tapsall JW. Antimicrobial testing and applications in the pathogenic Neisseria. In: Merlino J, ed. Antimicrobial Susceptibility Testing : Methods and Practices with an Australian Perspective. Sydney: Australian Society for Microbiology, 2004, pp. 175-188.
12. Tenover FC, et al. Ability of laboratories to detect emerging antimicrobial resistance : Proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing. Journal of Clinical Microbiology 2001; 39: 241-250.
13. Reyn A, et al. Results of comparative experiments using different methods for determining the sensitivity of Neisseria gonorrhoeae. Bulletin of the World Health Organization 1965; 32: 477-502.
14. Snell JJS, Brown DFJ. Antimicrobial susceptibility testing of Neisseria gonorrhoeae: a trial organised as part of the United Kingdom national external quality assessment scheme for microbiology. Journal of Clinical Pathology 1988; 41: 97-102.
15. Ison CA, et al. Comparability of laboratory diagnosis and antimicrobial susceptibility testing of Neisseria gonorrhoeae from reference laboratories in Western Europe. Journal of Antimicrobial Chemotherapy 2006; 58: 587-593.
16. Tapsall JW. Use of a quality assurance scheme in a long-term multicentric study of antibiotic susceptibility of Neisseria gonorrhoeae. Genitourinary Medicine 1990; 66: 8-13.
17. Bala M, Ray K, Gupta SM. Comparison of disc diffusion results with minimum inhibitory concentration (MIC) values for antimicrobial susceptibility testing of Neisseria gonorrhoeae. Indian Journal of Medical Research 2005; 122: 48-51.
18. Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Current Opinion Infectious Diseases 2009; 22: 87-89.
19. Lindberg R, et al. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone : association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrobial Agents and Chemotherapy 2007; 51: 2117-2122.
20. Bala M, et al. Changing trends of antimicrobial susceptibility patterns of Neisseria gonorrhoeae in India and the emergence of ceftriaxone less susceptible N. gonorrhoeae strains. Journal of Antimicrobial Chemotherapy 2007; 60: 582-586.